18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
Chiara Funaioli, Carmine Pinto, Francesca Di Fabio, Donatella Santini, Claudio Ceccarelli, Emilio De Raffaele, Stefano Fanti, Paolo Castellucci, Ciro Longobardi, Federico Buggi, Andrea Angelo Martoni
Around 20-30% of patients with hepatic metastasis from colorectal cancer can undergo liver resection, but the increased
response rate obtained with the addition of monoclonal antibodies to chemotherapy regimens could result in a higher rate of liver surgery. In this report we describe the
case of a patient who underwent a liver resection after neoadjuvant treatment with capecitabine, oxaliplatin and bevacizumab
and who achieved a complete pathological response of the liver metastasis. A preoperative CT scan demonstrated a partial response to the treatment while 18FDG-PET scan correctly evaluated the complete pathological response in the liver and detected an active interaortocaval
lymph node metastasis. New specific studies are required to evaluate the imaging response in metastatic colorectal
cancer patients especially after treatment with new, targeted agents.